DALLAS, Sept. 20, 2005 (PRIMEZONE) -- OTC Research.com has announced a new profile report on MIV Therapeutics, Inc. (OTCBB:MIVT). The report is authored by senior investment analyst, Shailesh Dhuri, CFA. In the report, Mr. Dhuri updates clients on the company's recent trading pattern and business development.
To view the report in its entirety, please visit: http://OTCResearch.com Registration is free.
OTC Research is committed to uncovering the real story on innovative, cutting-edge OTC-traded companies out there. With a potential universe of over 14,000 different public companies it is difficult, if not impossible, for the average investor to allocate the time and resources to finding the next "big thing." Our team of seasoned professionals includes several CFA's, professional traders, former brokers, accountants, and an economist -- to bring our members a comprehensive report on the companies we cover. This approach provides a more accurate and complete picture to investors as opposed to having a report authored solely by an analyst with no real-world experience in trading, management, or expertise in macro-economic events, as is the case at most research firms. Our reports reflect a consensus view from our entire team and do not rely on just one member's biased or limited viewpoint.
OTC Research (OTR) provides sponsored equity research of a wide range of industries for the institutional and investment communities. We certify that all the views expressed in this review accurately reflect our personal views about MIVT (OTCBB) and its or their securities. OTR has been compensated $3,300 from MIV Therapeutics for preparing this review. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review, and we will not have any investment banking relationships or consulting agreements in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This analysis and review does not have regard to the specific investment objectives, financial situation, and the information contained herein is based on sources that we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures regarding this security and all others on our website, http://www.OTCResearch.com.